Phase I/II: multicenter, open-label, single-arm. Phase 1: dose escalation (including PK run-in and subsequent cycles), patients with ALK+ advanced malignant solid tumors.Phase II: Part 1: patients with ROS+ and ALK + advanced NSCLC.Part 2: Cohort 1: patients who had not received systematic treatment or only received first-line non-ROS1-inhibitor treatment.Except for PK run-in phase (single dose), all patients should take SAF-189s orally once a day continuously with a treatment cycle of 21 days. Here, ALK is linked to non-small cell lung carcinoma.